Compare SFST & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFST | GRDN |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Retail-Drug Stores and Proprietary Stores |
| Sector | Finance | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.4M | 1.7B |
| IPO Year | 1999 | 2024 |
| Metric | SFST | GRDN |
|---|---|---|
| Price | $55.01 | $30.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $51.00 | $32.00 |
| AVG Volume (30 Days) | 47.0K | ★ 310.2K |
| Earning Date | 01-27-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.78 | N/A |
| EPS | ★ 3.23 | 0.28 |
| Revenue | $109,391,000.00 | ★ $1,389,638,000.00 |
| Revenue This Year | $13.23 | $19.50 |
| Revenue Next Year | $17.49 | $0.48 |
| P/E Ratio | ★ $17.04 | $110.34 |
| Revenue Growth | ★ 21.32 | 18.68 |
| 52 Week Low | $29.14 | $17.78 |
| 52 Week High | $56.73 | $37.43 |
| Indicator | SFST | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 79.06 | 56.51 |
| Support Level | $52.01 | $28.34 |
| Resistance Level | $52.65 | $31.46 |
| Average True Range (ATR) | 1.41 | 1.04 |
| MACD | 0.24 | 0.07 |
| Stochastic Oscillator | 77.39 | 55.02 |
Southern First Bancshares Inc is a bank holding company. The company engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer and mortgage loans to the general public of which a majority of the revenue is derived from the Commercial and Retail Banking segment which includes the provision of traditional deposit and lending products and services to its commercial and retail banking clients.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.